KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $168.7 million.

  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.71% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.7 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $166.4 million for FY2024, which is 1.35% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $168.7 million, which was up 0.81% from $167.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $168.7 million during Q3 2025, with a 5-year trough of $160.2 million in Q1 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $165.2 million in 2024 and averaged $165.3 million.
  • Data for Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 3.12% (in 2021) over the last 5 years.
  • Acadia Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $160.8 million in 2021, then grew by 0.92% to $162.2 million in 2022, then grew by 1.20% to $164.2 million in 2023, then increased by 1.35% to $166.4 million in 2024, then increased by 1.71% to $168.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $168.7 million in Q3 2025, compared to $167.4 million in Q2 2025 and $166.8 million in Q1 2025.